ArticleHereditas2025
BMAL1 alleviates sepsis-induced acute kidney injury by inhibiting apoptosis, ferroptosis and inflammation.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Research landscape and emerging themes of ferroptosis in sepsis-associated acute kidney injury: a bibliometric and science-mapping analysis (2016-2025).Frontiers in pharmacology · 2026Pooled it
- Cross-talk among novel programmed cell death pathways: a decisive network in renal ischemia-reperfusion injury.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSepsis is a life-threatening syndrome characterized by organ dysfunction. The kidney is one of the earliest organs to be injured during sepsis. Basic Helix-Loop-Helix ARNT Like 1 (BMAL1) was shown to play a critical role in immune responses. BMAL1 deregulation is related to sepsis-induced injury. Thus, correct understanding of the molecular mechanism of BMAL1 in sepsis-induced acute kidney injury (AKI) may be importance for seeking effective targeted therapy.
methodsLipopolysaccharide (LPS)-induced renal tubular epithelial cells (HK-2 cells) and a sepsis-AKI model established in C57BL/6 mice using cecal ligation and puncture (CLP) were used for functional analyses. In vitro analyses were conducted using EdU assay, flow cytometry, MTT assay and ELISA, respectively. Levels of mRNA and protein expression were using qRT-PCR and western blotting. Cellular ubiquitination analyzed the ubiquitination effect of USP10 on BMAL1. The binding of HOXA5 to BMAL1 promoter was verified using Chromatin immunoprecipitation and Luciferase reporter assays.
resultsBMAL1 overexpression reversed LPS-induced apoptosis, inflammation and ferroptosis in HK-2 cells, as well as attenuated sepsis-induced AKI in mouse models. Mechanistically, USP10 bound to BMAL1 and positively modulated BMAL1 expression by reducing BMAL1 ubiquitination. In addition, HOXA5 induced BMAL1 transcription. Moreover, USP10 or HOXA5 overexpression reversed LPS-induced apoptosis, inflammation and ferroptosis in HK-2 cells, which could be rescued by BMAL1 decrease.
conclusionBMAL1 overexpression mediated by USP10-induced deubiquitination or HOXA5-induced transcription can attenuate sepsis-induced acute kidney injury, recommending a novel insight for the prevention of sepsis-induced AKI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.